$BPTH
BIO-PATH HOLDINGS, INC.

2016 Q1 Form 10-K Financial Statement

#000114420416088178 Filed on March 15, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $850.0K $590.0K $2.460M
YoY Change 7.59% -32.18% -9.56%
% of Gross Profit
Research & Development $1.020M $870.0K $3.020M
YoY Change 72.01% -46.64% 85.28%
% of Gross Profit
Depreciation & Amortization $10.00K $50.00K $41.00K
YoY Change 0.0% 0.0% 310.0%
% of Gross Profit
Operating Expenses $1.869M $1.463M $5.485M
YoY Change 35.53% -8.74% 20.76%
Operating Profit -$1.869M -$1.463M -$5.484M
YoY Change 35.53% -8.74% 20.75%
Interest Expense $0.00 $0.00 $20.00K
YoY Change -100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $2.000K $5.000K $18.00K
YoY Change -50.0% -4.58% -21.74%
Pretax Income -$1.870M -$1.460M -$5.467M
YoY Change 36.5% -8.75% 19.89%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.867M -$1.458M -$5.467M
YoY Change 35.78% -8.75% 20.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.156M -$3.244M -$12.16M
COMMON SHARES
Basic Shares Outstanding 89.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.470M $8.850M $8.850M
YoY Change -48.03% -36.15% -36.15%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $1.360M $179.0K $740.0K
YoY Change 183.33% 78.12% 196.0%
Inventory
Prepaid Expenses $560.0K
Receivables
Other Receivables
Total Short-Term Assets $7.830M $9.593M $9.590M
YoY Change -39.49% -32.03% -32.03%
LONG-TERM ASSETS
Property, Plant & Equipment $62.00K $72.00K $70.00K
YoY Change -39.71% -36.35% -36.36%
Goodwill
YoY Change
Intangibles $1.050M $1.090M
YoY Change -13.28% -12.86%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.116M $1.162M $1.170M
YoY Change -14.81% -14.81% -14.6%
TOTAL ASSETS
Total Short-Term Assets $7.830M $9.593M $9.590M
Total Long-Term Assets $1.116M $1.162M $1.170M
Total Assets $8.946M $10.76M $10.76M
YoY Change -37.22% -30.51% -30.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $201.0K $54.00K $50.00K
YoY Change 151.25% 31.62% -64.29%
Accrued Expenses $699.0K $883.0K $880.0K
YoY Change 29.52% 248.4% 109.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $900.0K $937.0K $940.0K
YoY Change 46.05% 66.73% 67.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $900.0K $937.0K $940.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $900.0K $937.0K $940.0K
YoY Change 46.05% 66.73% 67.86%
SHAREHOLDERS EQUITY
Retained Earnings -$27.25M -$25.38M
YoY Change 27.45%
Common Stock $90.00K
YoY Change 0.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.050M $9.818M $9.820M
YoY Change
Total Liabilities & Shareholders Equity $8.950M $10.76M $10.76M
YoY Change -37.19% -30.51% -30.49%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$1.867M -$1.458M -$5.467M
YoY Change 35.78% -8.75% 20.98%
Depreciation, Depletion And Amortization $10.00K $50.00K $41.00K
YoY Change 0.0% 0.0% 310.0%
Cash From Operating Activities -$2.380M -$1.000M -$5.000M
YoY Change 68.79% -13.79% 30.89%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.380M -1.000M -5.000M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -2.380M -1.000M -5.000M
YoY Change 68.79% 29.87% -148.5%
FREE CASH FLOW
Cash From Operating Activities -$2.380M -$1.000M -$5.000M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.000M -$5.000M
YoY Change -9.91% 26.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17665 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-5466794 USD
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89762872 shares
CY2015 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
CY2014 us-gaap Revenues
Revenues
0 USD
CY2013 us-gaap Revenues
Revenues
0 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1630439 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1518885 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2715146 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1634650 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
4542246 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
3269240 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-4542246 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-3269240 USD
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
4037 USD
CY2014 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
335 USD
CY2013 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
810 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22297 USD
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3227 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-4519949 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-3266013 USD
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89281622 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71372672 shares
CY2015 us-gaap Revenues
Revenues
0 USD
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q2 dei Entity Public Float
EntityPublicFloat
94500000 USD
CY2015 dei Trading Symbol
TradingSymbol
BPTH
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89762872 shares
CY2014 us-gaap Adjustment For Amortization
AdjustmentForAmortization
160625 USD
CY2015Q4 us-gaap Cash
Cash
8854507 USD
CY2015 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-5004291 USD
CY2014Q4 us-gaap Cash
Cash
13858798 USD
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
22632 USD
CY2015 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
78483 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-123410 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.38 pure
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123410 USD
CY2013Q4 us-gaap Cash
Cash
3551832 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
404150 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0212 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0158 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.74 pure
CY2014Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
41026 USD
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M12D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13800000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2014Q4 us-gaap Other Inventory
OtherInventory
154667 USD
CY2015Q4 us-gaap Other Inventory
OtherInventory
559515 USD
CY2015Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
54581 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
882829 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
253445 USD
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3020027 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2464432 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
5484459 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-5484459 USD
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
17665 USD
CY2015 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2015 us-gaap Adjustment For Amortization
AdjustmentForAmortization
160625 USD
CY2015 us-gaap Depreciation
Depreciation
41137 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
404848 USD
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
375439 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5004291 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
368633 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2013 us-gaap Adjustment For Amortization
AdjustmentForAmortization
160625 USD
CY2014 us-gaap Depreciation
Depreciation
10284 USD
CY2013 us-gaap Depreciation
Depreciation
0 USD
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
103303 USD
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-143636 USD
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
36377 USD
CY2013 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
21542 USD
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
267073 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-34346 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3817497 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2313160 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13812373 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5330946 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14247873 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5330946 USD
CY2014 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
10306966 USD
CY2013 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
3017786 USD
CY2012Q4 us-gaap Cash
Cash
534046 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
704480 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2013Q4 bpth Authorised Capital To Be Raised
AuthorisedCapitalToBeRaised
100000000 USD
CY2014Q1 bpth Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
15000000 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.89 pure
CY2015 bpth Supply Agreement Consideration To Be Paid In Stages
SupplyAgreementConsiderationToBePaidInStages
1625000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
178977 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
100494 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
9592999 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
76779 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6640838 USD
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1550564 USD
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1110444 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5466794 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4560481 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3266013 USD
CY2015 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
89112 USD
CY2014 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
82333 USD
CY2013 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
217813 USD
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
131884 USD
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
131722 USD
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
90964 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
14113959 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123410 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
89763 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
89763 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
35112122 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
34743489 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25384039 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123410 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51421 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10284 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71989 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
113126 USD
CY2015Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2500374 USD
CY2014Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2500374 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1410106 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1249481 USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1090268 USD
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1250893 USD
CY2015Q4 us-gaap Assets
Assets
10755256 USD
CY2014Q4 us-gaap Assets
Assets
15477978 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
54581 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
41026 USD
CY2015Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0 USD
CY2014Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
100450 USD
CY2015Q4 bpth Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
0 USD
CY2014Q4 bpth Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
67050 USD
CY2015Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2014Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
100000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
937410 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
561971 USD
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2015Q4 us-gaap Liabilities
Liabilities
937410 USD
CY2014Q4 us-gaap Liabilities
Liabilities
561971 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19917245 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
9817846 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
14916007 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10755256 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15477978 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Concentration of Credit Risk &#151;</font></i></b> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. As a result, as of December 31, 2015, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.6</font> million of our cash balances was not covered by the FDIC. As of December 31, 2014 we had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.9</font> million in cash on-hand, of which approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.6</font> million was not covered by the FDIC.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Use of Estimates -</font></i></b> <font style="FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company&#8217;s estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5466794 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4519949 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3266013 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2015 us-gaap Interest Paid
InterestPaid
0 USD
CY2014 us-gaap Interest Paid
InterestPaid
0 USD
CY2013 us-gaap Interest Paid
InterestPaid
0 USD
CY2015 us-gaap Stock Issued1
StockIssued1
0 USD
CY2014 us-gaap Stock Issued1
StockIssued1
0 USD
CY2013 us-gaap Stock Issued1
StockIssued1
771047 USD
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
19531876 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1898618 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
48408 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
15725 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5025174 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3727259 USD
CY2015Q4 bpth Deferred Tax Assets Technology Licenses
DeferredTaxAssetsTechnologyLicenses
63534 USD
CY2014Q4 bpth Deferred Tax Assets Technology Licenses
DeferredTaxAssetsTechnologyLicenses
66697 USD
CY2013Q4 bpth Deferred Tax Assets Technology Licenses
DeferredTaxAssetsTechnologyLicenses
69859 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
877092 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
668611 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
520891 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
293324 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
256568 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
201490 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7964076 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6065458 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4535224 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7964076 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6065458 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4535224 USD
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1858710 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1530234 USD
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
945347 USD
CY2015 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0 USD
CY2014 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
21439 USD
CY2013 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0 USD
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
2864 USD
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
48280 USD
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
38248 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
82000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
84000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
86000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
51000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
303000 USD
CY2015Q1 us-gaap Revenues
Revenues
0 USD
CY2015Q2 us-gaap Revenues
Revenues
0 USD
CY2015Q3 us-gaap Revenues
Revenues
0 USD
CY2015Q4 us-gaap Revenues
Revenues
0 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
1378893 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
1130937 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
1512390 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
1462239 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1378893 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1130937 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1512390 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1462239 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4255 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5401 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4789 USD
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3220 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-1374638 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1125536 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1507601 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-1459019 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2014Q4 bpth Accounts Payable And Accrued Liabilities Related Party Current
AccountsPayableAndAccruedLiabilitiesRelatedPartyCurrent
167500 USD
CY2014Q1 us-gaap Revenues
Revenues
0 USD
CY2014Q2 us-gaap Revenues
Revenues
0 USD
CY2014Q3 us-gaap Revenues
Revenues
0 USD
CY2014Q4 us-gaap Revenues
Revenues
0 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
510210 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1274801 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
1154108 USD
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
1603127 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-510210 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
404150 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
368633 USD
CY2014Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
0 USD
CY2013Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
0 USD
CY2013Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
489501 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.33
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.51
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
914824 USD
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5751778 shares
CY2015 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
1.05
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5078611 shares
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1274801 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1154108 USD
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
1.00
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
368633 USD
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
636910 USD
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
404150 USD
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
704480 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
2014520 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
435500 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
704480 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1603127 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5334 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6024 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5699 USD
CY2014Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5240 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-504876 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1268777 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-1148409 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-1597887 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015 bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
60000 USD
CY2014 bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
175000 USD
CY2014Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15000000 USD
CY2015Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
22594 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1397957 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1187627 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
4783933 USD
CY2013 bpth Share Based Compensation Arrangement By Share Based Payment Award Vest And Exercisable Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestAndExercisablePeriod
Dec-13
CY2014 bpth Share Based Compensation Arrangement By Share Based Payment Award Vest And Exercisable Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestAndExercisablePeriod
Dec-14
CY2015 bpth Share Based Compensation Arrangement By Share Based Payment Award Vest And Exercisable Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestAndExercisablePeriod
Dec-15
CY2013 bpth Fund Raising Expense Period
FundRaisingExpensePeriod
Dec-13
CY2014 bpth Fund Raising Expense Period
FundRaisingExpensePeriod
Dec-14
CY2014 bpth Stock Options Exercised Issuance Period
StockOptionsExercisedIssuancePeriod
Dec-14
CY2014Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1250000 USD
CY2014Q4 us-gaap Other Finite Lived Intangible Assets Gross
OtherFiniteLivedIntangibleAssetsGross
2500000 USD
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5078611 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4734861 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4848298 shares
CY2013 bpth Net Loss
NetLoss
Dec-13
CY2014 bpth Net Loss
NetLoss
Dec-14
CY2015 bpth Net Loss
NetLoss
Dec-15
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
435500 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2015Q4 bpth Drug Supplier Commitments Development
DrugSupplierCommitmentsDevelopment
156250 USD
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
525000 shares
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-10085 USD
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD

Files In Submission

Name View Source Status
0001144204-16-088178-index-headers.html Edgar Link pending
0001144204-16-088178-index.html Edgar Link pending
0001144204-16-088178.txt Edgar Link pending
0001144204-16-088178-xbrl.zip Edgar Link pending
bpth-20151231.xml Edgar Link completed
bpth-20151231.xsd Edgar Link pending
bpth-20151231_cal.xml Edgar Link unprocessable
bpth-20151231_def.xml Edgar Link unprocessable
bpth-20151231_lab.xml Edgar Link unprocessable
bpth-20151231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tpg11a.jpg Edgar Link pending
tpg11b.jpg Edgar Link pending
tpg12.jpg Edgar Link pending
tpg13a.jpg Edgar Link pending
tpg13b.jpg Edgar Link pending
tpg15a.jpg Edgar Link pending
tpg15b.jpg Edgar Link pending
tpg4.jpg Edgar Link pending
tpg40.jpg Edgar Link pending
tpg5.jpg Edgar Link pending
tpg7.jpg Edgar Link pending
tpg8.jpg Edgar Link pending
tpg9a.jpg Edgar Link pending
tpg9b.jpg Edgar Link pending
v433524_10k.htm Edgar Link pending
v433524_ex21-1.htm Edgar Link pending
v433524_ex23-1.htm Edgar Link pending
v433524_ex31.htm Edgar Link pending
v433524_ex32.htm Edgar Link pending